AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate.
AMPA receptor GluRA subunits with mutations at position 750, a residue shown previously to control allosteric regulation by cyclothiazide, were analyzed for modulation of deactivation and desensitization by cyclothiazide, aniracetam, and thiocyanate. Point mutations from Ser to Asn, Ala, Asp, Gly, Gln, Met, Cys, Thr, Leu, Val, and Tyr were constructed in GluRAflip. The last four of these mutants were not functional; S750D was active only in the presence of cyclothiazide, and the remaining mutants exhibited altered rates of deactivation and desensitization for control responses to glutamate, and showed differential modulation by cyclothiazide and aniracetam. Results from kinetic analysis are consistent with aniracetam and cyclothiazide acting via distinct mechanisms. Our experiments demonstrate for the first time the functional importance of residue 750 in regulating intrinsic channel-gating kinetics and emphasize the biological significance of alternative splicing in the M3-M4 extracellular loop.
Partin
K M
KM
Laboratory of Cellular and Molecular Neurophysiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-4495, USA.
Fleck
M W
MW
Mayer
M L
ML
D017398:Alternative Splicing / Q000502:physiology; D000595:Amino Acid Sequence; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001581:Benzothiadiazines / Q000494:pharmacology*; D002460:Cell Line / Q000737:chemistry / Q000502:physiology; D005333:Fetus / Q000166:cytology; D005347:Fibroblasts / Q000737:chemistry / Q000502:physiology; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000235:genetics*; D007668:Kidney / Q000166:cytology; D007700:Kinetics; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed / Q000502:physiology; D018408:Patch-Clamp Techniques; D011760:Pyrrolidinones / Q000494:pharmacology*; D018091:Receptors, AMPA / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics*; D012680:Sensitivity and Specificity; D013861:Thiocyanates / Q000494:pharmacology*
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D011760:Pyrrolidinones; D018091:Receptors, AMPA; D013861:Thiocyanates; C036466:aniracetam; C031760:thiocyanate; C004639:cyclothiazide